Back to search
FDAFDA · Food and drugs·Recall number D-0059-2023

Fyarro (sirolimus protein-bound particles for injectable suspension (albumin-bound), 100 mg per vial, NDC 80803-153-50, manufactured for Aadi Bioscience, Inc, CA.

Published November 23, 2022 · Recall initiated: October 13, 2022

Summary

FDA records drug Class III recall D-0059-2023, published November 23, 2022 and initiated October 13, 2022. Recalling firm: Aadi Bioscience; Status: Terminated; Reported quantity: 2,333 vials; Lot: Lot# 6025701, Expiration Date: 31MAR2023, 100mg/vial, 50 ml single use vial, NDC 80803-153-50. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Stability Specifications

What to do

Voluntary: Firm initiated · Letter

Get an email if FYARRO has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
FYARRO
Manufacturer
Aadi Bioscience
Distributor
Within the U.S Market - PA, AL, KY, TN
Lot
Lot# 6025701, Expiration Date: 31MAR2023, 100mg/vial, 50 ml single use vial, NDC 80803-153-50.
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Fyarro (sirolimus protein-bound particles for injectable suspension (albumin-bound), 100 mg per vial, NDC 80803-153-50, manufactured for Aadi Bioscience, Inc, CA. recalled?

Yes. FDA published recall D-0059-2023 on November 23, 2022. Reported hazard: Failed Stability Specifications

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: FYARRO.